Thread by @DrMarthaGulati

#ESCCongress #LoDoCo2 Results #LBCT
Colchicine also a winner of @escardio 2020
This study was building on COLCOT results in secondary prevention in patients w/ chronic CAD
🔺5522 patients enrolled
🔺Randomized to Colchicine 0.5 mg vs Placebo
🔺Excluded advanced CKD, HF, valve ds

Characteristics of #LoDoCo2 #ESCCongress
🔺90% of patients tolerated medication
🔺Mostly men (84%)
🔺Most had prior revascularization
🔺 Most well treated

Results of #LoDoCo2 show dramatic effect of colchicine in these patients with chronic CAD
♥️30% reduction in treatment arm for Primary Outcome
♥️28% ⤵️ in MACE
♥️subgroup analysis shown
#ESCCongress #residualrisk #colchicine #inflammation

#LoDoCo2 #ESCCongress #LBCT
🔺Impressively well-tolerated drug in this cohort; no differences in SAE vs. placebo
🔺Findings summarized here but in Chronic CAD colchicine may reduce residual risk
🔺Is it time now to add this in with our patients we manage for secondary prevention?

So repurposing an old drug! #LoDoCo2 #ESCCongress
♥️Need to understand can interact with statins when we use colchicine
♥️need to monitor blood test when on this
♥️ May become part of secondary prevention to reduce residual risk